Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3721)	2/3/1998 3:10:00 PM
From: sam	Read Replies (1) \| Respond to of 6136

Any idea why VRTX has been trimmed the past two days?

To: David S. who wrote (3721)	2/3/1998 7:13:00 PM
From: Oliver & Co	Respond to of 6136

"Docs Say AZT Thwarts Other AIDS Drugs" United Press International (02/02/98); Susman, Ed ÿÿÿÿ Jean-Pierre Sommadossi, a professor at the University of Alabama-Birmingham, announced at the Fifth Conference on Retroviruses and Opportunistic Infections in Chicago that AZT may actually hinder the effectiveness of new AIDS drugs.ÿ He suggested that chemical reactions caused by AZT could interfere with HIV fighting mechanisms, which could be a reason why HIV becomes resistant to AZT and other drugs in combination therapy. In his study, Sommadossi found a 95 percent reduction of viral levels in patients given d4T who had not previously taken AZT, while those who were first treated with AZT and then d4T registeredÿ only a 60 percent to 70 percent drop.ÿ Sommadossi suggests that AZT may interfere with phosphorylation--a process used by antiretroviral drugs to release their virus-fighting abilities--which could explain why patients do not show as positive reactions to therapy when their combination regimen includes AZT.ÿ Other studies presented at the conference, however, challenge Sommadossi's findings.